国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
13期
1951-1954
,共4页
肾病综合征%水肿%托拉塞米%呋塞米%疗效
腎病綜閤徵%水腫%託拉塞米%呋塞米%療效
신병종합정%수종%탁랍새미%부새미%료효
Nephrotic syndrome%Edema%Torasemide%Furosemide%Curative effect
目的 探讨新型袢利尿剂托拉塞米注射液治疗儿童肾病综合征高度水肿的临床疗效.方法 对本科室2010年1月至2013年12月收治的肾病综合征患儿进行临床分析,将32例肾病综合征高度水肿患儿按随机数字表法分为托拉塞米组和呋塞米组,每组16例.两组在口服泼尼松足量[2 mg/(kg·d)或60 mg/(m2·d)]治疗的基础上,托拉塞米组静脉滴注托拉塞米1～2 mg/(kg·d),呋塞米组静脉滴注呋塞米1～2 mg/(kg·d),疗程为5d.两组患儿分别于治疗前、治疗后第2、4、6d检测24 h尿量、体重、血液生化各项指标的变化情况,并记录不良反应.结果 托拉塞米与呋塞米两组患儿临床疗效比较,尿量均较治疗前明显增加,水肿消退,体重减轻,两组总有效率之间差异有统计学意义(94％ vs.81％; x2=3.023,P＜0.05).呋塞米组患儿血钾浓度明显低于托拉塞米组(P＜0.05),血尿酸明显高于托拉塞米组(P＜0.05).结论 托拉塞米治疗儿童肾病综合征顽固性水肿,疗效显著,副作用小,对电解质及肾功能无明显影响,值得临床应用.
目的 探討新型袢利尿劑託拉塞米註射液治療兒童腎病綜閤徵高度水腫的臨床療效.方法 對本科室2010年1月至2013年12月收治的腎病綜閤徵患兒進行臨床分析,將32例腎病綜閤徵高度水腫患兒按隨機數字錶法分為託拉塞米組和呋塞米組,每組16例.兩組在口服潑尼鬆足量[2 mg/(kg·d)或60 mg/(m2·d)]治療的基礎上,託拉塞米組靜脈滴註託拉塞米1～2 mg/(kg·d),呋塞米組靜脈滴註呋塞米1～2 mg/(kg·d),療程為5d.兩組患兒分彆于治療前、治療後第2、4、6d檢測24 h尿量、體重、血液生化各項指標的變化情況,併記錄不良反應.結果 託拉塞米與呋塞米兩組患兒臨床療效比較,尿量均較治療前明顯增加,水腫消退,體重減輕,兩組總有效率之間差異有統計學意義(94％ vs.81％; x2=3.023,P＜0.05).呋塞米組患兒血鉀濃度明顯低于託拉塞米組(P＜0.05),血尿痠明顯高于託拉塞米組(P＜0.05).結論 託拉塞米治療兒童腎病綜閤徵頑固性水腫,療效顯著,副作用小,對電解質及腎功能無明顯影響,值得臨床應用.
목적 탐토신형번이뇨제탁랍새미주사액치료인동신병종합정고도수종적림상료효.방법 대본과실2010년1월지2013년12월수치적신병종합정환인진행림상분석,장32례신병종합정고도수종환인안수궤수자표법분위탁랍새미조화부새미조,매조16례.량조재구복발니송족량[2 mg/(kg·d)혹60 mg/(m2·d)]치료적기출상,탁랍새미조정맥적주탁랍새미1～2 mg/(kg·d),부새미조정맥적주부새미1～2 mg/(kg·d),료정위5d.량조환인분별우치료전、치료후제2、4、6d검측24 h뇨량、체중、혈액생화각항지표적변화정황,병기록불량반응.결과 탁랍새미여부새미량조환인림상료효비교,뇨량균교치료전명현증가,수종소퇴,체중감경,량조총유효솔지간차이유통계학의의(94％ vs.81％; x2=3.023,P＜0.05).부새미조환인혈갑농도명현저우탁랍새미조(P＜0.05),혈뇨산명현고우탁랍새미조(P＜0.05).결론 탁랍새미치료인동신병종합정완고성수종,료효현저,부작용소,대전해질급신공능무명현영향,치득림상응용.
Objective To study the clinical effects of torasemide in the treatment of nephrotic syndrome with intractable edema (referred to the infant nephropathy).Methods Clinical analysis was carried out to infants with kidney disease admitted in our department from January 2010 to December 2013,32 cases of infant kidney disease were divided into Torasemide group and Furosemide group,on the basis of the two oral prednisone sufficient quantities [2 mg/(kg · d) or 60 mg/(m2 · d)].Torasemide group,16 patients,were given intravenous infusion of torasemide 1-2 mg/(kg · d),Furosemide group with 16 cases were given intravenous infusion of furosemide 1-2 mg/(kg · d) for 5 days.The patients of two groups were detected for 24 h urine,electrolyte changes,and we recorded the adverse reactions before and after treatment of 2,4,6 days.Changes in the amount of urine,serum potassium and trioxypurine as the primary efficacy endpoint.Results Among the children of two groups with clinical use of torasemide and furosemide,urine output increased significantly as compared with that before treatment,showing edema fading,weight lose.Total efficiency in two groups was statistically significantly different (94％ vs 81％).Serum potassium concentration in Furosemide group was significantly lower than that of Torasemide group (P ＜ 0.05),trioxypurine concentration in Furosemide group was significantly higher than that of Torasemide group (P ＜ 0.05).Conclusion The torasemide in the treatment of nephrotic syndrome with intractable edema has significant clinical curative effect,with less side-effect,without obvious effect to electrolyte and renal function,which is worthy of clinical promotion.
